Can anything threaten Novo and Lilly’s obesity market dominance?
PharmaVoice
APRIL 21, 2025
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
PharmaVoice
APRIL 21, 2025
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
World of DTC Marketing
AUGUST 19, 2022
1ne: A new analysis predicts that by 2030, 48.9% Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 11, 2024
The new Eco Line product family demonstrates our commitment to delivering sustainable, eco-friendly barrier bottles at competitive prices,” added Bassi. As such, bottle weight is reduced by up to 30 percent without compromising on Water Vapor Transmission Rate (WVTR).
pharmaphorum
JULY 14, 2022
The two companies said the transaction is expected to close by the end of 2022, subject to approval by the competition authorities.
Sales Talent
JANUARY 20, 2022
However, before you jump directly to our sales hiring predictions for 2022, take the time to read the entire article to learn how the intense competition for talent is impacting sales professionals’ salaries and employers’ strategies for winning the talent war. jobs by 2030 while the workforce will only grow by 8.9M.
Pharmaceutical Technology
FEBRUARY 10, 2023
4DMT is creating a gene therapy using an adeno-associated viral vector (AAV) and there is currently competition from several early-stage therapies in trial, such as Sangamo Therapeutics’s Fabry gene therapy that is currently at Phase III, which also uses AAV, and as of November 2022 has reported it is progressing to late-stage plans.
European Pharmaceutical Review
DECEMBER 2, 2022
The time to population access for vaccines exceeds six years in a third of States, and the procurement mechanism for vaccines in most States doesn’t facilitate fair competition, timely access to vaccines and sustainable supply. The pipeline review determined there are disparities in market access to vaccines across Europe.
Pharmaceutical Technology
JUNE 7, 2023
Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.
pharmaphorum
JANUARY 19, 2023
Deuroxilitinib (formerly CTP-543) – a JAK 1/2 inhibitor – is coming up against drugs in the class from Eli Lilly and Pfizer in the alopecia areata market, so will face heavyweight competition, although Sun reckons it is a “best in class” therapy. The report predicts that the alopecia areata market will grow to as much as $2.5
European Pharmaceutical Review
SEPTEMBER 7, 2023
The UK’s association is set to create and support thousands of new job opportunities, helping to deliver the ambition to grow the economy and cement the UK as a science and technology superpower by 2030.
Pharmaceutical Technology
MAY 29, 2023
GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.
European Pharmaceutical Review
JANUARY 31, 2025
1 With pharmaceutical innovation increasingly focusing on a wider range of biotechnology-derived medicines, a surge in biological medicines losing market exclusivity is expected between now and the end of the decade, creating an opportunity eight times greater than that of the 2012-14 period, (peaking at 30 billion between 2030-2032).
LEVO Health
JANUARY 10, 2025
Between 2023 and 2030, that number is expected to grow at a compound annual growth rate of 22.6%. Additionally, incorporating elements like leaderboards and challenges can foster a sense of competition among patients, further driving engagement. In 2022, the global healthcare gamification market was valued at 3.15 billion dollars.
LEVO Health
JANUARY 13, 2025
The AI healthcare market is projected to reach a value of $188 billion by 2030. Therefore, it’s crucial for healthcare organizations to understand the intersection of AI and patient experience to stay competitive and provide the best care possible.
Medico Reach
OCTOBER 17, 2022
from 2022 to 2030. The potential increase in industry competition could also spell trouble for some. Grand View Research published a report recently that captured some interesting highlights about the orthopedic medical device industry. The article puts the global market size for the sector at $40.9
pharmaphorum
NOVEMBER 8, 2022
” Lilly is trying to stay ahead of rivals Novo Nordisk and Sanofi in an increasingly competitive insulin market, as well as tapping into the trend to make medicines safer and more effective through the use of digital technologies. billion in 2020 to more than $16 billion by 2030, according to GlobalData.
European Pharmaceutical Review
MARCH 24, 2023
According to GlobalData, competition to develop a first-to-market drug for NASH is strong. In the European Union, NASH affects nearly 10 million people and is expected to increase by more than 40 percent by 2030. 89bio is one of several companies advancing treatments. It is becoming the leading cause for liver transplants.
Clarify Health
APRIL 18, 2024
As both government and commercial payers direct a greater share of volume to out-patient facilities and patient demand for same-day service increases, opportunity and competition in the ambulatory surgical center (ASC) space are increasing. Is there an ASC in your market you should merge with or acquire?
pharmaphorum
JANUARY 16, 2023
The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.
Contrarian Sales Techniques
JANUARY 30, 2023
According to the Bureau of Labor Statistics, employment of medical and pharmaceutical sales representatives is projected to grow 3 percent from 2020 to 2030, about as fast as the average for all occupations. However, the industry is becoming more competitive and navigating the industry is becoming harder.
Contrarian Sales Techniques
NOVEMBER 19, 2024
On the other hand, original manufacturers often face tough competition, as the market becomes flooded with alternatives. It’s a dynamic that keeps the industry competitive and ensures patients benefit from a range of choices. For pharma sales reps, this shift changes the conversation. In 2022, it was valued at approximately $898.7
pharmaphorum
JANUARY 4, 2023
The Proposal hopes to address the concerns with the current system and support the EC’s vision for the EU’s digital transformation by 2030. It has been proposed that the amount of these fees charged by the data holder must be transparent, proportionate, and “must not restrict competition” 10. Rights for individuals.
Every Ancillary
MAY 14, 2021
According to one estimate from P&S Research , this market is expected to grow nearly 5x by 2030! Cons: Highly competitive with new options continually emerging. The Regenerative Medicine sector has exploded in popularity in recent years, with that trend expected to continue for the foreseeable future.
European Pharmaceutical Review
DECEMBER 21, 2022
16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. In the context of CO 2 neutrality, the years 2030 and 2050 are mentioned as crucial milestones.
Medico Reach
OCTOBER 17, 2022
from 2022 to 2030. The potential increase in industry competition could also spell trouble for some. Grand View Research published a report recently that captured some interesting highlights about the orthopedic medical device industry. The article puts the global market size for the sector at $40.9
LEVO Health
MAY 8, 2024
Top Strategies to Improve Patient Engagement in Healthcare Practices must consistently attract and retain patients to stay ahead in the competitive healthcare market. By 2030, that number is expected to rise to over 187 billion dollars. Therefore, the role of AI in patient engagement is set to grow exponentially.
Spotio
FEBRUARY 9, 2023
Furthermore, the organization predicts it will outpace the GDP by 2030. Increased competition Your sales team also faces more competition than ever before. This method won’t cut it in years to come if you expect to separate yourself from the competition. The medical field is growing. What does this look like?
Healthcare Success
NOVEMBER 14, 2022
billion in 2030 ). Differentiating medical devices can be challenging due to commoditization and the fast pace of technological advances, but it’s critical to stand out in a competitive device market. Over the next seven years, the medical device market will nearly double in size (from USD 495.46 billion in 2022 to 964.90
Spotio
MARCH 25, 2024
In fact, experts claim that 15% of American households will have solar photovoltaic (PV) systems in place by 2030. This indicates enormous potential for solar companies—but competition for business is fierce. Your company will be compared to the competition to see how it stacks up. If it can’t, it won’t.
Pharmaceutical Technology
JUNE 19, 2023
According to a GlobalData epidemiology forecast, there will be nearly 190 million cases of dysphagia globally by 2030. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.
Pharmaceutical Technology
JUNE 15, 2023
Led by a multidisciplinary committee of patient advocacy leaders, healthcare professionals, biosimilar experts, and industry leaders from across the globe, it aims to increase biosimilar adoption by 30 percentage points in over 30 countries by 2030. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.
Medico Reach
JANUARY 7, 2025
million by 2030, growing at a CAGR of 26.3%, showcasing it as a testament to the industry’s potential for expansion and innovation. Similarly, for chiropractors, staying informed and engaged with these trends is key to staying ahead of the competition. It is leading to attain a staggering market valuation of USD 2,871.8
Pharmaceutical Technology
JANUARY 11, 2023
By 2030, global spending on digital health is projected to represent 8% of all healthcare expenditure, up from 3% currently 2. Funding has followed the technology, with the digital health sector seeing significant growth globally due to strong investor confidence and perceived investment opportunities.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
Medico Reach
FEBRUARY 8, 2023
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. from 2023 to 2030. Now is the time for various B2B businesses targeting the pharma industry to buckle up, get competitive and align their strategies for propensity. Poised to grow at a CAGR of 29.4%
pharmaphorum
OCTOBER 10, 2022
The pharma group said earlier this year it is hoping for eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, and thrombosis as well as PAH, that will swell its sales from in the category to $10 billion around the end of the decade.
Pharmaceutical Technology
NOVEMBER 23, 2022
Lifted by increased interest after the onset of the Covid-19 pandemic, the sector is expected to balloon to US$853 billion by 2030. Hamilton offers more competitive prices than Toronto and the city is only an hour away from its larger neighbour. City Competitiveness Index. per square foot (/ft2) in Hamilton, versus C$9.06/ft2
PM360
AUGUST 9, 2022
ZS analysis shows the top pharma companies have more than $230B in worldwide revenues at risk from 2022 to 2030; the top 10 pharma companies combined have more than 45% of their revenues at risk. Ask: Is this component truly a competitive advantage? During this time, 69 blockbusters will lose patents. The Payoff Is Real.
Pharmaceutical Technology
MAY 22, 2023
billion) by 2030. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. The UK government also has its own plans for funding research. billion ($18.2 Horizon Europe has a budget of €95.5
Clarivate
MAY 31, 2023
Pharma M&A activity was muted in 2022, coming in at its lowest level since 2013 – something of a surprise, given the looming patent cliff and pharma’s past reliance on M&A and biopartnering as a quick fix for revenues lost to generics and biosimilars competition. billion based on seven preclinical ADC candidates.
Pharmaceutical Technology
JULY 21, 2022
Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.
European Pharmaceutical Review
SEPTEMBER 1, 2023
billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. Omega Therapeutics’s share suggests increasing competition and diversification in this innovative field,” concluded Podder. Global RNA therapy clinical trials market to reach $3.5 subvariant.
Pharmaceutical Technology
MAY 26, 2023
Touchlight estimates that the DNA market is currently worth $1bn and will grow 20% annually until 2030. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.
Pharmaceutical Technology
DECEMBER 15, 2022
The BioPIPS project is in line with Singapore’s wider “Manufacturing 2030” program, which aims to boost the country’s manufacturing by 50%. According to GlobalData’s Contract Service Provider database, Merck & Co currently owns three facilities in Singapore, and Novartis and GSK each own two facilities.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content